AI reveals insights into link between CD33 and cognitive impairment in Alzheimer’s Disease
Fig 6
Predicted changes on phenotype (MMSE and Braak stages) as a consequence of CD33 down-expression.
Distribution of MMSE and Braak stages in CD33 original (blue) and down-expressed (red) patients shows a significant improvement of scores and thus cognition as well as brain pathophysiology.